ArticleScientific reports2025
Systemic immune-inflammation index and serum lactate dehydrogenase predict the prognosis of non-metastatic nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic Value of Hemoglobin, Albumin, Lymphocyte, and Platelet Score in Locally Advanced Nasopharyngeal Carcinoma.Cancer medicine · 2026Article
- Machine learning prognostication in nasopharyngeal carcinoma: a european multicentre analysis of survival and risk of second malignancy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Downregulation of miR-10b-3p by EBV promotes tumor growth and metastasis via ITGAV in nasopharyngeal carcinoma.PLoS pathogens · 2026Article
- Serum lactate dehydrogenase and vascular endothelial growth factor A level as a predictor of treatment response in locally advanced-stage World Health Organisation type 3 nasopharyngeal carcinoma.Contemporary oncology (Poznan, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Increasing evidence indicates that the systemic immune-inflammation index (SII) and lactate dehydrogenase (LDH) are correlated with the prognosis of various malignancies. This study aimed to evaluate the prognostic value of pre-treatment SII and LDH in patients with non-metastatic nasopharyngeal carcinoma (NPC). We conducted a retrospective analysis of 756 patients with non-metastatic NPC. The optimal cut-off values for SII and LDH, determined using X-tile software, were 150 and 447, respectively. Independent prognostic factors for survival outcomes were identified using Kaplan-Meier analysis and Cox regression analysis. Patients in the high SII group had significantly worse prognosis in 5-year OS (76.5 vs. 86.7%, p < 0.001), 5-year DMFS (77.3 vs. 85.4%, p < 0.001), and 5-year PFS (67.9 vs. 80.5%, p < 0.001) compared to the low SII group. Patients in the high LDH group had significantly worse prognosis in 5-year OS (72.1 vs. 85.0%, p < 0.001), 5-year DMFS (72.1 vs. 84.8%, p < 0.001), and 5-year PFS (63.7 vs. 77.7%, p < 0.001) compared to the low LDH group.Multivariate analysis showed that high SII and high LDH were significantly associated with poorer OS (p = 0.005 vs.p < 0.001), DMFS(p = 0.001 vs.p < 0.001), and PFS (p = 0.001 vs.p < 0.001). These results confirmed that both SII and LDH are independent prognostic factors for OS, DMFS, and PFS. In subgroup analysis, this predictive effect was more pronounced in locally advanced stages. Among patients with locally advanced NPC, the combination of SII and LDH showed the highest AUC values for predicting OS, DMFS, and PFS. Pre-treatment SII and LDH are important prognostic factors in patients with non-metastatic NPC. Furthermore, the combination of both provides a more accurate prognosis for patients with locally advanced NPC than either marker alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.